Author

K. I. Savage

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Thompson· 1 shared C. M. Crean· 1 shared D. I. Johnston· 1 shared D. P. Harkin· 1 shared E. E. Parkes· 1 shared E. M. Barros· 1 shared F. G. Liberante· 1 shared J. S. Smitth· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Thompson

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Chronic loss of STAG2 leads to altered chromatin structure contributing to de-regulated transcription in AML

J. S. Smitth, S. G. Craig, F. G. Liberante, K. M. Lappin, C. M. Crean, S. S. McDade, A. Thompson, K. Mills, K. I. Savage

This study shows that chronic STAG2 loss alters chromatin structure and deregulates transcription in AML, affecting HOXA and MAPK pathways.

bioRxiv · Nov 26, 2019Cancer Biology

Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation

R. D. A. Wilkinson, N. McCabe, E. E. Parkes, E. M. Barros, D. I. Johnston, R. Ali, K. Lappin, R. Greenberg, D. P. Harkin, S. A. McIntosh, R. D. Kennedy, K. I. Savage

This study shows topo-II inhibitors like doxorubicin induce cGAS-STING dependent inflammation, cytokine production, and immune checkpoint activation in cancer cells, enhancing potential for immune checkpoint blockade therapy.

bioRxiv · Oct 24, 2019 · PreprintCancer Biology